Prognostic factors correlated with survival in AIDS patients

European Journal of Epidemiology

Volumn 15, Issue 8, 1999, Pages 691-698

  Casari, Salvatore ^a,c   Donisi, A ^a   Paraninfo, G ^b   Tomasoni, D ^a   Palvarini, L ^a   Nasta, P ^a   Bergamasco, A ^a   Cadeo, G P ^b   Carosi, G ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b 1st Department of Infectious Diseases   (Italy)

^c SPEDALI CIVILI   (Italy)

Author keywords

AIDS; Prognostic factors; Survival

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CANDIDIASIS; CONTROLLED STUDY; CRYPTOSPORIDIOSIS; CYTOMEGALOVIRUS INFECTION; FEMALE; HUMAN; KAPOSI SARCOMA; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PNEUMOCYSTIS PNEUMONIA; PROGNOSIS; SURVIVAL RATE; SURVIVAL TIME; TOXOPLASMOSIS; TUBERCULOSIS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; FEMALE; HUMANS; ITALY; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS;

EID: 0032747060     PISSN: 03932990     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007676625117     Document Type: Article

References (21)

1. Batalla J, Gatell JM, Cayla JA, Plascencia A, Jansa JM, Parellada N. Predictors of the survival of AIDS cases in Barcelona - Spain. AIDS 1989; 3: 355-359.
2. Friedland GH, Saltzman B, Vileno J, Freeman K, Schrager LK, Klein RS. Survival differences in patients with AIDS. J AIDS 1991; 4: 144-153.
3. D'Arminio-Monforte A, Mainini F, Bini T, et al. Fattori di rischio, patologie diagnostiche e sopravvivenza in una coorte di 547 pazienti affetti da AIDS. Giorn Ital AIDS 1992; 3(2): 85-90.
4. Fahey IL, Taylor JMG, Detels R, et al. The prognostic value of cellular and serologic markers in infection with Human Immunodeficiency Virus type 1. N Engl J Med 1990; 322(3): 166-72.
5. Enger C, Graham N, Peng Y, Chmiel JS, Kingsley LA, Detels R, Muñoz A. Survival from early, intermediate and late stages of HIV infection. JAMA 1996; 275: 1329-1334.
6. Muñoz A, Vlahov D, Solomon L, et al. Prognostic indicators for development of AIDS among intravenous drug users. J AIDS 1992; 5: 694-700.
7. Kehui L, Matthew L, Kaldor JM, Mc Donald AM, Cooper DA. The role of initial AIDS-defining illness in survival following AIDS. AIDS 1995; 9: 57-63.
8. Chaisson RE, Keruly JC, Moore RD. Race, sex, drug use and progression of Human Immunodeficiency Virus disease. N Engl J Med 1995; 333(12): 751-756.
9. Volberding PA, Lagakos SW, Grimes JM, et al. The duration of zidovudine benefit in persons with asymptomatic HIV infection. Prolonged evaluation of protocol 019 of the AIDS Clinical Trials Group. JAMA 1994; 272(6): 437-442.
10. Dorrell L, Snow MH, Ong EL. Mortality and survival trends in patients with AIDS in North-East England from 1984-1992. J Infect 1995; 30(1): 23-27.
11. Kalbfleisch JD, Prentice RL. The Statistical analysis of failure time data. New York: John Wiley & Sons, 1980.
12. Pulido F, Peña JM, Rubio R, et al. Survival of HIV infected patients after an episode of Tuberculosis (TB). Is TB always an AIDS event? In: 35th ICAAC, San Francisco 17-20 sett. 1995, Abstr. K 124, 309.
13. Stein DS, Graham NM, Park LP, Hoover DR, Phair JP, Detels R, Ho M, Saah AJ. The effect of the interaction of acyclovir with zidovudine on progression to AIDS and survival. Analysis of data in the Multicenter AIDS Cohort Study. Ann Intern Med 1994; 121(2): 100-108.
14. Sabin CA, Phillips AN, Lee CA, Janossy G, Emery V, Griffiths PD. The effect of CMV infection on progression of Human Immunodeficiency virus disease in a cohort of haemophilic men followed up to 13 years from seroconvertion. Epidemiol Infect 1995; 114(2): 361-372.
15. Ocular Complications of AIDS Research Group, Antiviral effects of Foscarnet and Ganciclovir therapy on Human Immunodeficiency Virus p24 antigen in patients with AIDS and Cytomegalovirus retinitis. J Infect Dis 1995; 172(3): 613-621.
16. Gallant JE, Moore RD, Keruly J, Richman DD, Chaisson RE. Lack of association between acyclovir use and survival in patients with advanced Human Immunodeficiency Virus disease treated with zidovudine. J Infect Dis 1995; 172(2): 346-352.
17. Ward JW, Hanson DL, Chu SY, Jones JJ. Survival and trends in anti-retroviral therapy and antimicrobial prophylaxis among persons with 1993-defined AIDS. In: 35th ICAAC, San Francisco 17-20 sett. 1995, Abstr. I 168, 235.
18. Saravolatz L, Neaton JD, Sacks L, Deyton L, Rhame F, Sherer R. CD4+ T-Lymphocyte counts and patterns of mortality among patients infected with Human Immunodeficiency Virus who were enrolled in community programs for clinical research on AIDS. Clin Infect Dis 1996; 22: 513-520.
19. Apolonio EG, Hoover DR, He Y, et al. Prognostic factors in Human Immunodeficiency Virus-positive patients with a CD4+ Lymphocyte count < 50/μl. J Infect Dis 1995; 171: 829-836.
20. Bindels PJE, Krol A, Roos M, Veenstra J, van den Hoek JAR, Miedema F, Coutinho RA. The predictive value of T cell function in vitro and pre-AIDS zidovudine use for survival after AIDS diagnosis in a cohort of homosexual men in Amsterdam. J Infect Dis 1995; 172: 97-104.
21. Vella S, Giuliano M, Floridia M, et al. Effect of sex, age and transmission category on the progression to AIDS and survival of zidovudine-treated symptomatic patients. AIDS 1995; 9: 51-56.